Literature DB >> 6252930

The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison.

A J Shorthouse, M J Peckham, J F Smyth, G G Steel.   

Abstract

The chemotherapeutic response of a series of patients with bronchial carcinoma has been compared with the response of their xenografts established in immune-suppressed CBA/lac mice. Xenograft response was assessed by the in situ endpoint of growth delay in subcutaneous tumours. Histology and chromosome analysis indicated that human characteristics were retained in the xenografts. 49 xenograft lines were attempted: 15/18 oat cell, 11/17 squamous, 6/8 large cell anaplastic and 6/6 adenocarcinomas were successfully established. 14 Lines (28%) were available (August 1979) for direct comparison of xenograft and donor patient response to the same chemotherapeutic agents. A positive correlation was found and provides support for the chemotherapeutic validity of xenografts.

Entities:  

Mesh:

Year:  1980        PMID: 6252930      PMCID: PMC2149243     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  3 in total

1.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

Review 2.  The growth and therapeutic response of human tumours in immune deficient mice.

Authors:  G G Steel
Journal:  Bull Cancer       Date:  1978       Impact factor: 1.276

3.  Improved immune-suppression techniques for the exongrafting of human tumours.

Authors:  G G Steel; V D Courtenay; A Y Rostom
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

  3 in total
  20 in total

1.  Cell proliferation in human tumours growing in nude mice: renal cell carcinomas, larynx and hypopharynx carcinomas.

Authors:  B Maurer-Schultze; I D Bassukas; M Böswald; M Harasim
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Studying lung cancer in the laboratory: 1--Development of model systems.

Authors:  R J Fergusson; J F Smyth
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

Review 3.  Studying lung cancer in the laboratory--2: Chemosensitivity testing.

Authors:  R J Fergusson; J F Smyth
Journal:  Thorax       Date:  1987-11       Impact factor: 9.139

Review 4.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

5.  Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).

Authors:  A C Jones; P A Wilson; G G Steel
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 6.  Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients.

Authors:  P J Selby; D Raghavan
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

7.  Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinoma.

Authors:  R J Fergusson; J Carmichael; J F Smyth
Journal:  Thorax       Date:  1986-05       Impact factor: 9.139

Review 8.  Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments.

Authors:  P Zarzosa; N Navarro; I Giralt; C Molist; A Almazán-Moga; I Vidal; A Soriano; M F Segura; R Hladun; A Villanueva; S Gallego; J Roma
Journal:  Clin Transl Oncol       Date:  2016-10-07       Impact factor: 3.405

9.  Activity of a new nitrosourea (TCNU) in human lung cancer xenografts.

Authors:  R J Fergusson; L E Anderson; J S Macpherson; P Robins; J F Smyth
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

10.  Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.

Authors:  E Kjellén; J Wennerberg; R Pero
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.